Actively Recruiting
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Led by Takeda · Updated on 2025-10-07
1890
Participants Needed
1
Research Sites
443 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this survey is to evaluate the long-term safety and efficacy of leuprorelin acetate injection kit 11.25 mg in patients with spinal and bulbar muscular atrophy (SBMA) in the routine clinical setting.
CONDITIONS
Official Title
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of spinal and bulbar muscular atrophy (SBMA)
- Currently receiving the leuprorelin acetate injection kit 11.25 mg treatment
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Takeda Selected Site
Tokyo, Japan
Actively Recruiting
Research Team
T
Takeda Study Registration Call Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here